State, Federal Lawmakers Aim to Bar PBMs From Owning Pharmacies - MedPage Today
Lawmakers are proposing to prohibit Pharmacy Benefit Managers (PBMs) from owning pharmacies, which could impact the operational landscape for pharmacies and manufacturers.
Aforeworn detected this change in the Pharmaceutical Manufacturing (FDA/DEA) space on September 7, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated Medium urgency. All pharmacies and pharmaceutical manufacturers involved with PBMs. should confirm how it applies to their specific situation before acting. There is a time constraint attached: No specific deadline mentioned; ongoing legislative process.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmaceutical Manufacturing (FDA/DEA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
Proposed legislation aims to bar PBMs from owning pharmacies, potentially altering the business model for pharmacies and impacting drug pricing and access.
Who it affects
All pharmacies and pharmaceutical manufacturers involved with PBMs.
What you must do
Monitor the progress of the legislation and assess potential impacts on pharmacy operations and relationships with PBMs.
Deadline
No specific deadline mentioned; ongoing legislative process.
Never miss a change like this again
Aforeworn watches Pharmaceutical Manufacturing (FDA/DEA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Pharmaceutical Manufacturing (FDA/DEA)
- Trump Releases More Federal Marijuana Prisoners As DEA Considers Rescheduling Cannabis - Marijuana Moment
- Novartis Wins Temporary Pause of FDA’s Entresto Generic Approval - Bloomberg Law News
- Oklahoma judge OK’s $85 million settlement with Teva Pharma over opioids - MarketWatch
- Biotech company testing psilocybin pill requests preemptive change in Kansas law - Kansas Reflector
- Kansas AG’s proposed restriction on mifepristone would impact more than abortion patients - kansasreflector.com